作者
Benjamin J. R. Buckley,Linda Long,Deirdre A. Lane,Signe Stelling Risom,Charlotte Fitzhugh,Selina Kikkenborg Berg,Pernille Palm,Kirstine Lærum Sibilitz,Jesper Hastrup Svendsen,Christian Gluud,Ann‐Dorthe Zwisler,Gregory Y.H. Lip,Lis Neubeck,R Taylor
摘要
Objective To undertake a contemporary review of the impact of exercise based cardiac rehabilitation (ExCR) for patients with atrial fibrillation (AF). Data sources CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, WoS Core Collection, LILACS and trial registers were searched from inception up to 24 March 2024. Eligibility criteria Randomised clinical trials (RCTs) comparing ExCR with any non-exercise control. Design Random effect meta-analyses presented as effect estimates and 95% CIs. Meta-regression examined study level effect modification. Cochrane risk of bias, GRADE (Grading of Recommendations Assessment, Development and Evaluation) and trial sequential analysis (RTSA) were applied. Results 20 RCTs (n=2039) with a mean follow-up of 11 months showed that ExCR did not impact all cause mortality (8.3% vs 6.0%, relative risk (RR) 1.06, 95% CI 0.76 to 1.48) or serious adverse events (2.9% vs 4.1%, RR 1.30, 95% CI 0.66 to 2.56) but did reduce AF symptom severity (mean difference (MD) −1.61, 95% CI −3.06 to −0.16), AF burden (MD −1.61, 95% CI −2.76 to −0.45), episode frequency (MD −0.57, 95% CI −1.07 to −0.07), episode duration (MD −0.58, 95% CI −1.14 to −0.03), AF recurrence (RR 0.68, 95% CI 0.53 to 0.89), and improved exercise capacity (maximal oxygen consumption (VO 2 peak) MD 3.18, 95% CI 1.05 to 5.31 mL/kg/min). There was benefit for the mental component but not the physical component of a health related quality of life questionnaire. No differential effects across AF subtype, ExCR dose, or mode of delivery were seen. Conclusion Meta-analyses of RCT evidence for ExCR in patients with AF demonstrated several clinical benefits without an increase in serious adverse events. GRADE and RTSA assessments indicated further high quality and adequately powered RCTs are needed.